达帕格列嗪
磷酸西他列汀
医学
体质指数
内科学
2型糖尿病
前瞻性队列研究
糖尿病
内分泌学
作者
Kota Takuma,Ayako Fuchigami,Fumika Shigiyama,Naoki Kumashiro,Takahisa Hirose
摘要
Abstract Aims To compare the effects of baseline background characteristics in patients treated with dapagliflozin and sitagliptin in the DIVERSITY‐CVR study and to analyse the time in range (TIR), a metric for glycaemic control. Materials and methods This prospective, randomized, multicentre study included 340 Japanese patients with early‐stage type 2 diabetes. To examine the effects of dapagliflozin and sitagliptin on glycaemic variability, we re‐examined the primary endpoint (glycated haemoglobin [HbA1c] < 7.0%, body weight loss ≥ 3.0%, and avoidance of hypoglycaemia) achievement rate in participants stratified by baseline background characteristics. Results Sitagliptin was significantly superior in achieving HbA1c level <7.0% in the lower body mass index (BMI) group (71.1% vs. 43.6%; P < 0.05), with no significant differences in other subgroups. In the lower BMI group, the rate of achievement of TIR > 70% after 24‐week treatment was significantly higher with sitagliptin than with dapagliflozin (91.9% vs. 69.4%; P < 0.05). In contrast, dapagliflozin was superior to sitagliptin in achieving TIR > 70% in the higher BMI group (85.7% vs. 52.9%; P < 0.01). Conclusion In Japanese patients with early‐stage type 2 diabetes, sitagliptin was associated with improved TIR in patients with a lower BMI. Dapagliflozin was effective in patients with a higher BMI.
科研通智能强力驱动
Strongly Powered by AbleSci AI